Skip to main content
Premium Trial:

Request an Annual Quote

Prodesse Flu Assay Gets Additional FDA Claims

NEW YORK (GenomeWeb News) – Molecular diagnostics company Prodesse said today that the US Food and Drug Administration has authorized two changes to the packaging on the company’s influenza assay.
 
The FDA, which cleared the company’s ProFlu+ at the beginning of 2008, has accepted using the bioMérieux NucliSENS easyMAG automated nucleic acid extraction system with the ProFlu+ test, the company said.
 
The FDA also has removed a recommendation that negative results for influenza A and influenza B should be confirmed by culture. That makes this test the first molecular test for respiratory viruses that the FDA has decided does not require a backup, the Milwaukee, Wis.-based company said.
 
Prodesse CEO Tom Shannon said that “only a test that shows exceptional performance compared to culture can have this recommendation removed.”
 
The ProFlu Assay is designed to simultaneously detect and differentiate influenza A and B viruses and respiratory syncytial virus, and provides results in around three hours.
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.